Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial finds the appropriate parsaclisib dose level in combination with
romidepsin for the treatment of T-cell lymphomas that have come back (relapsed) or that have
not responded to standard treatment (refractory). The other goals of this trial are to find
the proportion of patients whose cancer is put into complete remission or significantly
reduced by romidepsin and parsaclisib, and to measure the effectiveness of romidepsin and
parsaclisib in terms of patient survival. Romidepsin blocks certain enzymes (histone
deacetylases) and acts by stopping cancer cells from dividing. Parsaclisib is a PI3K
inhibitor. The PI3K pathway promotes cancer cell proliferation, growth, and survival.
Parsaclisib, thus, may stop the growth of cancer cells by blocking PI3K enzymes needed for
cell growth. Giving romidepsin and parsaclisib in combination may work better in treating
relapsed or refractory T-cell lymphomas compared to either drug alone.